Posted 16th November 2017 by Jane Williams
By any measure, momentum in the microbiome space keeps building. The 2017 Silicon Valley Bank mid-year Microbiome Investment Trends report provides one of the most up-to-date snapshots: close to USD 1 billion has been invested in microbiome companies globally since 2010, and SVB’s analysts predict the total capital in disclosed equity investments in 2017 alone could be reaching north of USD 400 million by year-end. And my own analysis of Microbiome Partnership Trends, published earlier this year, documents the dramatic increase in partnerships during 2016, a trend that has shown no signs of slowing down.
Posted 13th November 2017 by Jane Williams
Irritable Bowel Syndrome (IBS) is one of the most common gastrointestinal disorders, affecting 10-15% of adults.(1) Abdominal pain, alterations of bowel habits; bloating and flatulence; straining and urgency are all common symptoms.(1)
Posted 6th November 2017 by Jane Williams
Last week’s blog gave an overview of the oral microbiome. In part two, the focus is on dysbiosis and associated illness.
Posted 30th October 2017 by Jane Williams
New understanding of the microbiome is changing ideas about health and is pertinent to our thinking about the role of the oral microbiome in systemic disease. This article gives an overview of the oral microbiome, while next week’s will focus on dysbiosis and associated illness.
Posted 23rd October 2017 by Jane Williams
More accurately, between 150 and 200 species of plant, insect, bird or mammal go extinct every day.
These species are ones that we can see. We have no idea what the global extinction rate is for microbes and very few people have even thought about it.
Posted 12th October 2017 by Jane Williams
Microbial ecology, our understanding of what determines the robustness and community dynamics of microbial consortia, and synthetic biology, the art of engineering microorganisms to perform particular physiological or metabolic functions, are rapidly becoming allies in the race to develop novel therapeutic strategies in the microbiome space.
Posted 4th October 2017 by Jane Williams
Interest in microbiota has reached all areas of human health and disease. As a result, the therapeutic potential of probiotics has expanded. 2013 saw a surge of investment into prebiotics and probiotics, coinciding with an increase in microbiome funding. In the last decade, investment has quadrupled.
Posted 25th September 2017 by Jane Williams
Colorectal cancer (CRC) is the result of a series of histopathological changes starting with the appearance of outbreaks of aberrant crypts (AC) in the colon and generally leading to adenocarcinoma. CRC is one of the third most common diagnosed cancers in western countries.